Objectives: recognizing pharmacists' increasing roles as primary care providers, programs offering remuneration for patient care services and the administration of injections by pharmacists continue to be implemented. the objective of this article is to provide an update on remuneration programs available to pharmacists internationally for nondispensing services.
SYSTEMATIC rEvIEw
could identify only 28 examples of remuneration programs. We updated that review in 2014 2 and reported 60 remuneration programs. In the updated review, we noted that the average fee paid for a medication review was $CDN 68.76 ($US 52.59), a follow-up visit was $CDN 23.37 ($US 17.85) and a prescription adaptation was $CDN 15.16 ($US 11.58). A similar review was also published looking specifically at remuneration offered for the administration of injections by pharmacists. 3 Across both of those reports,
we noted that there were few programs that measured pharmacists' uptake of these services and impact on patient outcomes. We also identified that this was a very fast-changing area and that, as such, it would be of interest to update the review periodically to capture new and revised program details.
Objective
The purpose of the present report is to provide an update on remuneration programs for pharmacists' clinical care services.
Methods
Consistent with the previous reviews, pharmacists' patient care services were defined as "those that enhanced a patient's medication therapy or overall health and did not include medication preparation or distribution or any tasks that could be delegated to a [pharmacy technician or assistant]. " 1,2 This definition therefore excludes routine medication counselling associated with dispensing, routine clozapine laboratory monitoring without concurrent intervention or care plan development, and provision of self-testing kits without clinical intervention. We also excluded technical tasks, according to the current scope of practice for regulated pharmacy technicians. In Canada, 9 provinces currently recognize pharmacy technicians as regulated health professionals 4 after the successful completion of Pharmacy Examining Board of Canada examinations and other province-specific requirements. 5 Because the technician scope of practice includes the ability to "instruct patients about the operation and maintenance of medical devices, " 6 programs that reimburse pharmacists/ pharmacies for medical device training were also excluded from this review. The administration of drugs or vaccines by injection was defined as the administration of any substance by parenteral route by a pharmacist. This definition excludes the provision of a naloxone kit for patient use, because the pharmacist is paid for dispensing, counselling and education, not administration of the drug.
Search strategy
Literature searches were performed by a research librarian in the following databases: PubMed (MEDLINE), Ovid Embase, Ovid International Pharmaceutical Abstracts, Cochrane Library, Proquest's Econlit, Scopus and Web of Science. The search strategies were derived from the previous reviews and updated to include terms related to specific types of cognitive services offered, including immunization, vaccination, smoking cessation and minor ailments assessment and prescribing. To construct the searches, a combination of medical subject headings and keywords related to payment, remuneration, reimbursement, pharmacy, pharmacists and various clinical services was included. In addition, depending on database functionality, the adjacency operator, truncation and phrase searching were used. All searches were limited to the date range of January 2013 to February 2018 and search results were exported into Refworks citation management software for duplicate removal. Full search strategies are available from the authors on request. To identify additional relevant articles, the bibliographies of included
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• A systematic review of remuneration for pharmacists' clinical care services was initially published in 2008, followed by a review of remuneration for the administration of injections in 2013 and an update of the clinical care services review in 2014.
• High variability in fees and patient eligibility criteria were noted across all reviews. It was also noted that this is an area of rapid growth and change, requiring regular review.
• the purpose of this article is to update those reviews according to literature retrieved through February 2018.
• Ninety-five new remunerated programs for pharmacist-performed noninjection clinical care services and 37 new programs for pharmacist-administered injections were identified since the last review.
• Other than smoking cessation services in the United Kingdom, all services were remunerated on a fee-for-service basis.
• consistent with previous reviews, great variability exists regarding pharmacists' scope of practice, fees offered and patient eligibility criteria for remunerated programs.
SYSTEMATIC rEvIEw studies and tables of contents for pharmacy practice journals were reviewed for additional citations.
To complement the searches for published literature, a search for gray literature was conducted. Targeted websites were searched, including the Institute of Health Economics, the Canadian Agency for Drugs and Technologies in Health, Health Action International, the International Society for Pharmacoeconomics and Outcomes Research, the Organisation for Economic Co-operation and Development, the Pharmaceutical Group of the European Union, Proquest's Dissertations and Theses and the World Health Organization. Comprehensive online searches for publicly available information were also performed, beginning with the programs and jurisdictions included in the previous reviews, to specifically look for expansions in programs or changes in patient eligibility criteria or fees offered. Searches of publicly available information from pharmacy associations of all Canadian provinces, US states and other countries with eligible programs mentioned in the previous reviews were performed as well. Associations were contacted individually by e-mail for clarification or additional information as required. Pharmacy provider manuals for state Medicaid programs in the United States were also reviewed for each state. We excluded fees specifically offered to pharmacists through the Vaccines for Children programs across the country. Websites of each of the Local Pharmaceutical Committees of the United Kingdom were also manually searched, because these committees negotiate pharmacy services with local commissioners. The search engine Google was then used to identify any additional programs, incorporating the same search terms as applied to the database searches.
Study selection
Citations were identified that were published from January 2013 to February 2018. Programs were included if they described remuneration programs for pharmacist clinical care services or injection administration in any setting and were not included in the previous review or if they were reported in the previous review but had changes to patient eligibility criteria and/ or fees. Remuneration had to be offered through a third-party payer (government, employer or insurance plan), be separate from dispensing fees and excluded services paid out-of-pocket by patients. Programs were also excluded if they were offered only as part of a funded research study or pilot project or had fewer than 3 participating pharmacies, because we were specifically interested in reporting on ongoing and broadly applicable remuneration programs. Finally, programs where the billing was not done directly through a pharmacist were excluded. This therefore excluded any programs where the pharmacist-performed service is billed for using "incident to" billing, wherein the service is billed under a physician's provider number and the nonphysician provider of the care is considered an employee of the physician who provides this care under physician supervision.
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Data extraction
One author screened titles and abstracts for inclusion and performed data extraction. Owing to heterogeneity in this subject area and among different health systems observed from previous reviews, data were reported descriptively.
Results
The database search resulted in 2729 citations, and 218 titles were identified for full-text review (Appendix 1, available online at www.cpjournal. ca). Of these, 209 were excluded for the following reasons: no report on a remuneration program (n = 75), full text could not be retrieved (n = 51), report of a program described in a previous review with no changes to patient eligibility or fees (n = 21), program offered in fewer than 3 pharmacies (n = 18), results reported only in abstract form (n = 15), report of a demonstration or pilot program (n = 13), report on a program offered only within the context of a research study rather than an ongoing program (n = 10) and payment provided in the form of "incident to" billing (n = 6). The remaining 9 studies 8-16 prompted specific gray literature searches on those programs to verify the eligibility of the program for the review and to extract details on patient eligibility and payment offered, if eligible. In total, 178 records from the gray literature were ultimately included in this review in addition to the 9 published studies, for a total of 187 records.
Clinical care services excluding injections
A total of 95 new remunerated programs and services were identified since the last review, with SYSTEMATIC rEvIEw 1 additional program having incomplete information available (Appendix 2, available online).
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Thirteen programs that were previously reported had changes in patient eligibility criteria and fees offered.
Injection administration
A total of 37 new remunerated programs/services were introduced since the last review and 6 were previously reported but had changes in patient eligibility criteria and fees offered (Table  1) . As with the previous reviews, a large degree of variation was noted in types of services offered, patient eligibility criteria and fees offered ( Almost all services were remunerated on a fee-for-service basis, with only smoking cessation services in the United Kingdom being remunerated based on outcome. In the UK program, pharmacies providing the service were equipped with point-of-care carbon monoxide monitors to verify patients' smoking status. A pharmacy that had a patient with a verified quit at 4, 8 and 12 weeks qualified for an incentive payment ranging from £5 to £200 ($7.05-$281.88). Nonverified (patient self-report) quits qualified for incentive payments ranging from £4 to £82 ($5.64-$115.57). Some commissioning groups offered additional bonuses based on patient characteristics, including the following: In the present review, we saw 2 of those 3 common ambulatory programs expand to include several new conditions, and we saw a Canadian province add such a program. Similarly, several jurisdictions now allow pharmacists to renew, adapt or initiate a prescription, and we continue to see new remuneration programs emerging to support these services. We also saw an expansion in medication review programs that support pharmacists in following up with patients after an initial review. This is consistent with the findings of a meta-analysis by Kwint et al. 197 that pharmacist recommendations are more likely to be implemented after a medication review if the pharmacist follows up (among several other factors, such as if the pharmacist has clinical experience, if the pharmacist is the patient's regular pharmacist and has access to medical records, if the SYSTEMATIC rEvIEw physician referred the patient for review, if the pharmacist and physician hold a case conference and if there is an action plan). However, evaluation of the diabetes-focused MedsCheck program in Ontario, Canada, showed that although one-half of all patients with diabetes in the province had received a medication review from a pharmacist, only 3% had received a follow-up, despite a funding mechanism in place. 198 This is a useful reminder that remuneration is not the only barrier to comprehensive pharmacy care and that other issues, such as time constraints, organizational workflow and a culture/workplace setting that supports taking responsibility for patient care, need to be addressed to ensure that programs can be implemented as designed.
Another important point to consider is that although medication reviews consistently SYSTEMATIC rEvIEw improve outcomes related to conditions such as hypertension, diabetes and cholesterol in the research setting, 199 they tend to be less effective in the real world. For example, an evaluation of the British Columbia pharmacist medication review services found that uptake by pharmacists was very low, one-half of reviews were not policy concordant, prescription drug use did not change and the reviews were associated with an overall increase in physician visits.
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An evaluation of the Ontario MedsCheck program found that people who took more medications were less likely to be offered a medication review. 202 Similarly, a review of research on the Australia Home Medicines Review and Clinical Medicines Review programs noted that awareness and service delivery is low for more vulnerable populations, including those who are indigenous or who are culturally and linguistically diverse. 203 It is notable that these studies have all contributed to changes in those medication review programs, suggesting that regular evaluation is a key component of an effective medication review program. These experiences also highlight some of the planning considerations for new medication review programs, including clear patient eligibility criteria, expectations that pharmacists will provide follow-up, the inclusion of billing codes that facilitate largescale evaluation and, importantly, an a priori plan for evaluation of the program. The expansion in programs offering remuneration for pharmacist-administered injections reflects recent expansions of pharmacist scope of practice to include injection administration across a number of Canadian provinces (Manitoba, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Saskatchewan), France and New Zealand since the previous review. Interestingly, each of these new regions SYSTEMATIC rEvIEw currently limits remunerated vaccine administration to the influenza vaccine only. Among jurisdictions that offered some remuneration for pharmacist-administered vaccines in the previous review, adoption was noted across a number of state Medicaid programs in the United States, with trends across many programs toward expanding the range of vaccines eligible for remuneration to include a number of those that are part of national or regional routine immunization schedules. These findings are consistent with an analysis of pharmacist vaccination laws in the United States from 1971 to 2016, which noted overall expansion in legislation related to pharmacist-administered vaccines, with lessening restrictions related to patient age and physician oversight. 204 Because a number of vaccines require only single doses, annual doses (e.g., influenza) or booster doses at multipleyear intervals, concerns noted with insufficient follow-up after an initial intervention with services such as medication reviews are less prevalent for vaccinations. However, as the scope of eligible vaccines that pharmacists can administer expands to include travel vaccinations or vaccinations for children, pharmacists will need to adopt processes, such as reminder systems, to ensure the completion of multiple-dose series.
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One of the main concerns with remuneration programs for pharmacy services is value for money. A cost-utility analysis in Spain suggested that a medication review with follow-up is costeffective 206 and that for every €1 spent on the service, €3.3 to €6.2 is saved. 207 Similarly, a recent cost-effectiveness analysis of pharmacist hypertension services in Canada estimated that pharmacist involvement in hypertension management could save more than $CDN 6000 over a patient's lifetime and $CDN 15.7 billion over a time horizon of 30 years if rolled out population-wide. 208 Economic evaluations continue to emerge and will be key to establishing sustainable programs in the long term.
It should be noted that our review is not exhaustive. One of the main limitations of the review is that we had to rely on publicly available information. This may have excluded programs offered solely between private payers and pharmacies as part of a proprietary program. We also attempted to obtain information on commissioned services offered by each of the approximately 80 Local Pharmaceutical Committees in the United Kingdom. However, many did not make their fee data publicly available. In particular, we were unable to verify or obtain information on many of the services referenced in a database of locally commissioned services that is maintained by the Pharmaceutical Services Negotiating Committee. Finally, we also excluded vaccine programs for children, because most programs outside of the United States do not allow pharmacists to vaccinate young children.
Conclusion
Opportunities for pharmacists to receive publicly funded remuneration for nondispensing patient care services continue to expand. However, high levels of variation (even within the same geographic region) related to scope of practice recognized by different payers, patient eligibility for services and fees offered make direct comparisons among programs difficult. Large ranges in fees offered for similar services suggest that some programs may generate revenue whereas others may be insufficient to offset the costs of offering the service. Payers and pharmacists are encouraged to investigate the time and other resources required to offer a service of high quality to ensure that these programs can be offered to the patients who would most benefit from them within the business model of community pharmacy practice. Ongoing evaluation of all remuneration programs for pharmacists' services is also strongly encouraged to assess uptake and outcomes. ■ 
